A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement

Massimiliano Filosto; Giuseppe Rossi; Anna Maria Pelizzari; Serena Buzio; Marta Tentorio; Laura Broglio; Michelangelo Mancuso; Marianna Rinaldi; Mauro Scarpelli; Alessandro Padovani

doi:10.1016/j.jns.2007.05.023

A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement

J Neurol Sci. 2007 Dec 15;263(1-2):40-3. doi: 10.1016/j.jns.2007.05.023. Epub 2007 Jul 5.

Authors

Massimiliano Filosto¹, Giuseppe Rossi, Anna Maria Pelizzari, Serena Buzio, Marta Tentorio, Laura Broglio, Michelangelo Mancuso, Marianna Rinaldi, Mauro Scarpelli, Alessandro Padovani

Affiliation

¹ Clinical Neurology, Section for Neuromuscular Diseases and Neuropathies, University Hospital "Spedali Civili", Brescia, Italy. filosto@med.unibs.it

PMID: 17612569
DOI: 10.1016/j.jns.2007.05.023

Abstract

Bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma, is known to induce an axonal, dose-dependent neuropathy clinically characterized by pain, paresthesias, burning dysesthesias and numbness. In this study, we describe a patient treated with high-dose bortezomib whose main clinical feature was severe sensory ataxia. Electrodiagnostic studies showed, other than axonal changes, myelin involvement.

Publication types

Case Reports

MeSH terms

Aged
Ataxia / drug therapy*
Ataxia / pathology*
Ataxia / physiopathology
Boronic Acids / therapeutic use*
Bortezomib
Dose-Response Relationship, Drug
Humans
Male
Myelin Sheath / drug effects
Myelin Sheath / physiology*
Neural Conduction / drug effects
Neural Conduction / physiology
Protease Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Reaction Time / drug effects
Reaction Time / physiology

Substances

Boronic Acids
Protease Inhibitors
Pyrazines
Bortezomib